Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Organogenesis Holdings Inc.ORGO · Entity 6275 | Director · President and CEO | February 18, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Organogenesis Holdings Inc.
Report date February 18, 2026 · Filed March 03, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 4,232,087 |
Last balance in matching sequence
After 2026-02-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-02-18 · Grant · Acquired 188,856 · Balance 4,323,398 F1: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Row 2 · 2026-02-18 · Tax withholding · Disposed 91,311 · Balance 4,232,087 F1: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2022 Filed May 31, 2022 21:16 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 56,362 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-22-013879 · form4.xml · derivative · entry 8 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,574 Underlying: Class A Common Stock · 56,362 shares Expires 2024-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| May 27, 2022 Filed May 31, 2022 21:16 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 56,362 | $5.93 | $334,226.66 |
DisclosureSEC source: 0001062993-22-013879 · form4.xml · nonDerivative · entry 4 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,242 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.62 to $5.98, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| May 27, 2022 Filed May 31, 2022 21:16 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 56,362 | $0.99 | $55,798.38 |
DisclosureSEC source: 0001062993-22-013879 · form4.xml · nonDerivative · entry 3 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2022 Filed May 31, 2022 21:16 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 61,202 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-22-013879 · form4.xml · derivative · entry 7 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,936 Underlying: Class A Common Stock · 61,202 shares Expires 2024-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| May 26, 2022 Filed May 31, 2022 21:16 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 61,202 | $5.71 | $349,463.42 |
DisclosureSEC source: 0001062993-22-013879 · form4.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,242 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.55 to $5.875, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| May 26, 2022 Filed May 31, 2022 21:16 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 61,202 | $0.99 | $60,589.98 |
DisclosureSEC source: 0001062993-22-013879 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2022 Filed May 25, 2022 22:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 84,674 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-22-013521 · form4.xml · derivative · entry 12 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,138 Underlying: Class A Common Stock · 84,674 shares Expires 2024-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| May 25, 2022 Filed May 25, 2022 22:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 84,674 | $5.60 | $474,174.40 |
DisclosureSEC source: 0001062993-22-013521 · form4.xml · nonDerivative · entry 8 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,242 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.47 to $5.72, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. Read SEC document |
| May 25, 2022 Filed May 25, 2022 22:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 84,674 | $0.99 | $83,827.26 |
DisclosureSEC source: 0001062993-22-013521 · form4.xml · nonDerivative · entry 7 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 482,916 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 24, 2022 Filed May 25, 2022 22:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 52,312 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-22-013521 · form4.xml · derivative · entry 11 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 558,812 Underlying: Class A Common Stock · 52,312 shares Expires 2024-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| May 24, 2022 Filed May 25, 2022 22:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 52,312 | $5.66 | $296,085.92 |
DisclosureSEC source: 0001062993-22-013521 · form4.xml · nonDerivative · entry 6 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,242 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.60 to $5.73, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| May 24, 2022 Filed May 25, 2022 22:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 52,312 | $0.99 | $51,788.88 |
DisclosureSEC source: 0001062993-22-013521 · form4.xml · nonDerivative · entry 5 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 23, 2022 Filed May 25, 2022 22:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 53,680 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-22-013521 · form4.xml · derivative · entry 10 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 611,124 Underlying: Class A Common Stock · 53,680 shares Expires 2024-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| May 23, 2022 Filed May 25, 2022 22:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,670 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-22-013521 · form4.xml · derivative · entry 9 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,067,245 Underlying: Class A Common Stock · 6,670 shares Expires 2024-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| May 23, 2022 Filed May 25, 2022 22:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 53,680 | $5.80 | $311,344.00 |
DisclosureSEC source: 0001062993-22-013521 · form4.xml · nonDerivative · entry 4 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,242 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.705 to $5.93, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| May 23, 2022 Filed May 25, 2022 22:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 6,670 | $5.84 | $38,952.80 |
DisclosureSEC source: 0001062993-22-013521 · form4.xml · nonDerivative · entry 3 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 451,922 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.70 to $6.05, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| May 23, 2022 Filed May 25, 2022 22:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 53,680 | $0.99 | $53,143.20 |
DisclosureSEC source: 0001062993-22-013521 · form4.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 458,592 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 23, 2022 Filed May 25, 2022 22:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 6,670 | $0.99 | $6,603.30 |
DisclosureSEC source: 0001062993-22-013521 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 404,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2022 Filed May 20, 2022 22:13 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 58,654 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-22-013178 · form4.xml · derivative · entry 9 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,073,915 Underlying: Class A Common Stock · 58,654 shares Expires 2024-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| May 20, 2022 Filed May 20, 2022 22:13 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 58,654 | $5.89 | $345,472.06 |
DisclosureSEC source: 0001062993-22-013178 · form4.xml · nonDerivative · entry 6 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,242 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.75 to $6.04, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| May 20, 2022 Filed May 20, 2022 22:13 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 58,654 | $0.99 | $58,067.46 |
DisclosureSEC source: 0001062993-22-013178 · form4.xml · nonDerivative · entry 5 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2022 Filed May 20, 2022 22:13 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 118,504 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-22-013178 · form4.xml · derivative · entry 8 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,132,569 Underlying: Class A Common Stock · 118,504 shares Expires 2024-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| May 19, 2022 Filed May 20, 2022 22:13 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 118,504 | $5.94 | $703,913.76 |
DisclosureSEC source: 0001062993-22-013178 · form4.xml · nonDerivative · entry 4 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,242 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.45 to $6.11, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| May 19, 2022 Filed May 20, 2022 22:13 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 118,504 | $0.99 | $117,318.96 |
DisclosureSEC source: 0001062993-22-013178 · form4.xml · nonDerivative · entry 3 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 516,746 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2022 Filed May 20, 2022 22:13 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 86,531 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-22-013178 · form4.xml · derivative · entry 7 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,251,073 Underlying: Class A Common Stock · 86,531 shares Expires 2024-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| May 18, 2022 Filed May 20, 2022 22:13 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 86,531 | $5.46 | $472,459.26 |
DisclosureSEC source: 0001062993-22-013178 · form4.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,242 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.39 to $5.62, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| May 18, 2022 Filed May 20, 2022 22:13 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 86,531 | $0.99 | $85,665.69 |
DisclosureSEC source: 0001062993-22-013178 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 484,773 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2022 Filed May 18, 2022 00:11 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 98,078 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-22-012849 · form4.xml · derivative · entry 12 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,337,604 Underlying: Class A Common Stock · 98,078 shares Expires 2024-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| May 17, 2022 Filed May 18, 2022 00:11 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 98,078 | $5.90 | $578,660.20 |
DisclosureSEC source: 0001062993-22-012849 · form4.xml · nonDerivative · entry 8 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,242 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.83 to $6.06, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. Read SEC document |
| May 17, 2022 Filed May 18, 2022 00:11 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 98,078 | $0.99 | $97,097.22 |
DisclosureSEC source: 0001062993-22-012849 · form4.xml · nonDerivative · entry 7 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 496,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2022 Filed May 18, 2022 00:11 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 80,369 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-22-012849 · form4.xml · derivative · entry 11 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,435,682 Underlying: Class A Common Stock · 80,369 shares Expires 2024-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| May 16, 2022 Filed May 18, 2022 00:11 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 80,369 | $5.92 | $475,784.48 |
DisclosureSEC source: 0001062993-22-012849 · form4.xml · nonDerivative · entry 6 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,242 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.77 to $6.13, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| May 16, 2022 Filed May 18, 2022 00:11 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 80,369 | $0.99 | $79,565.31 |
DisclosureSEC source: 0001062993-22-012849 · form4.xml · nonDerivative · entry 5 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 478,611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2022 Filed May 18, 2022 00:11 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 121,580 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-22-012849 · form4.xml · derivative · entry 10 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,516,051 Underlying: Class A Common Stock · 121,580 shares Expires 2024-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| May 13, 2022 Filed May 18, 2022 00:11 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,810 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-22-012849 · form4.xml · derivative · entry 9 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 505,050 Underlying: Class A Common Stock · 14,810 shares Expires 2023-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| May 13, 2022 Filed May 18, 2022 00:11 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 121,580 | $6.18 | $751,364.40 |
DisclosureSEC source: 0001062993-22-012849 · form4.xml · nonDerivative · entry 4 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,242 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $6.06 to $6.32, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| May 13, 2022 Filed May 18, 2022 00:11 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 14,810 | $6.06 | $89,748.60 |
DisclosureSEC source: 0001062993-22-012849 · form4.xml · nonDerivative · entry 3 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 519,822 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $6.01 to $6.16, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| May 13, 2022 Filed May 18, 2022 00:11 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 121,580 | $0.99 | $120,364.20 |
DisclosureSEC source: 0001062993-22-012849 · form4.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2022 Filed May 18, 2022 00:11 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 14,810 | $0.99 | $14,661.90 |
DisclosureSEC source: 0001062993-22-012849 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 22:20 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 9,789 | $7.89 | $77,235.21 |
DisclosureSEC source: 0001062993-22-009815 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,242 Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 23:50 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 4,085 | $7.78 | $31,781.30 |
DisclosureSEC source: 0001062993-22-004794 · form4.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 408,031 Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 23:50 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 664,532 | $0.00 Strike: $8.03 | $0.00 |
DisclosureSEC source: 0001062993-22-004794 · form4.xml · derivative · entry 3 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 664,532 Underlying: Class A Common Stock · 664,532 shares Expires 2032-02-15 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 23:50 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 280,199 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-004794 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,116 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2022. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 00:45 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 160,237 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001661181-21-000062 · edgar.xml · derivative · entry 9 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 519,860 Underlying: Class A Common Stock · 160,237 shares Expires 2023-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 00:45 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 160,237 | $14.02 | $2,246,522.74 |
DisclosureSEC source: 0001661181-21-000062 · edgar.xml · nonDerivative · entry 6 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,917 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2021. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.61 to $14.38, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 00:45 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 160,237 | $0.99 | $158,634.63 |
DisclosureSEC source: 0001661181-21-000062 · edgar.xml · nonDerivative · entry 5 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2021 Filed Jul 21, 2021 00:45 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 115,450 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0001661181-21-000062 · edgar.xml · derivative · entry 8 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 465,392 Underlying: Class A Common Stock · 115,450 shares Expires 2030-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option became and continues to become exercisable in equal annual installments over four years beginning April 1, 2020. Read SEC document |
| July 16, 2021 Filed Jul 21, 2021 00:45 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,313 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001661181-21-000062 · edgar.xml · derivative · entry 7 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 680,097 Underlying: Class A Common Stock · 24,313 shares Expires 2023-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| July 16, 2021 Filed Jul 21, 2021 00:45 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 29,434 | $15.33 | $451,223.22 |
DisclosureSEC source: 0001661181-21-000062 · edgar.xml · nonDerivative · entry 4 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,917 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2021. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.85, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| July 16, 2021 Filed Jul 21, 2021 00:45 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 110,329 | $14.58 | $1,608,596.82 |
DisclosureSEC source: 0001661181-21-000062 · edgar.xml · nonDerivative · entry 3 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,351 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2021. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.27 to $14.99, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.